Currency In USD
| Previous Close | 0.57 |
| Open | 0.58 |
| Day High | 0.59 |
| Day Low | 0.53 |
| 52-Week High | 2.54 |
| 52-Week Low | 0.16 |
| Volume | 6.72M |
| Average Volume | 13.72M |
| Market Cap | 107.92M |
| PE | -0.84 |
| EPS | -0.69 |
| Moving Average 50 Days | 0.8 |
| Moving Average 200 Days | 0.76 |
| Change | 0 |
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire Inc.
Mar 05, 2026 9:15 PM GMT
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update followi
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
GlobeNewswire Inc.
Feb 19, 2026 2:00 PM GMT
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership adv
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
GlobeNewswire Inc.
Feb 11, 2026 1:45 PM GMT
ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submi